"Didanosine" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A dideoxynucleoside compound in which the 3'-hydroxy group on the sugar moiety has been replaced by a hydrogen. This modification prevents the formation of phosphodiester linkages which are needed for the completion of nucleic acid chains. Didanosine is a potent inhibitor of HIV replication, acting as a chain-terminator of viral DNA by binding to reverse transcriptase; ddI is then metabolized to dideoxyadenosine triphosphate, its putative active metabolite.
Descriptor ID |
D016049
|
MeSH Number(s) |
D03.633.100.759.590.616.130 D13.570.230.500.090 D13.570.583.616.130 D13.570.800.573.130
|
Concept/Terms |
Didanosine- Didanosine
- Dideoxyinosine
- 2',3'-Dideoxyinosine
- 2',3' Dideoxyinosine
- ddI (Antiviral)
|
Below are MeSH descriptors whose meaning is more general than "Didanosine".
Below are MeSH descriptors whose meaning is more specific than "Didanosine".
This graph shows the total number of publications written about "Didanosine" by people in this website by year, and whether "Didanosine" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
Year | Major Topic | Minor Topic | Total |
---|
2002 | 1 | 0 | 1 |
2003 | 1 | 0 | 1 |
2007 | 1 | 0 | 1 |
2008 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Didanosine" by people in Profiles.
-
Castelnuovo B, John L, Lutwama F, Ronald A, Spacek LA, Bates M, Kamya MR, Colebunders R. Three-year outcome data of second-line antiretroviral therapy in Ugandan adults: good virological response but high rate of toxicity. J Int Assoc Physicians AIDS Care (Chic). 2009 Jan-Feb; 8(1):52-9.
-
McKinney RE, Rodman J, Hu C, Britto P, Hughes M, Smith ME, Serchuck LK, Kraimer J, Ortiz AA, Flynn P, Yogev R, Spector S, Draper L, Tran P, Scites M, Dickover R, Weinberg A, Cunningham C, Abrams E, Blum MR, Chittick GE, Reynolds L, Rathore M. Long-term safety and efficacy of a once-daily regimen of emtricitabine, didanosine, and efavirenz in HIV-infected, therapy-naive children and adolescents: Pediatric AIDS Clinical Trials Group Protocol P1021. Pediatrics. 2007 Aug; 120(2):e416-23.
-
Sanne I, Piliero P, Squires K, Thiry A, Schnittman S. Results of a phase 2 clinical trial at 48 weeks (AI424-007): a dose-ranging, safety, and efficacy comparative trial of atazanavir at three doses in combination with didanosine and stavudine in antiretroviral-naive subjects. J Acquir Immune Defic Syndr. 2003 Jan 1; 32(1):18-29.
-
Skowron G, Kuritzkes DR, Thompson MA, Squires KE, Goodwin SD, Dusak BA, Tolson JM, Stevens M, Yuen GJ, Rooney JF. Once-daily quadruple-drug therapy with adefovir dipivoxil, Lamivudine, Didanosine, and efavirenz in treatment-naive human immunodeficiency virus type 1-infected patients. J Infect Dis. 2002 Oct 1; 186(7):1028-33.